Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
About this item
Full title
Author / Creator
Publisher
China: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
China: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathway that drives cancer cells to proliferate and metastasize. RAS‐driven oncogenesis also promotes immune evasion by i...
Alternative Titles
Full title
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9aa12d1d00174415864d60bceb9ad752
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9aa12d1d00174415864d60bceb9ad752
Other Identifiers
ISSN
2688-2663
E-ISSN
2688-2663
DOI
10.1002/mco2.10
